Completed OBSERVATIONAL NCT00831714

Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty (XAMOS)

Xarelto in the Prophylaxis of Post Surgical Venous Thromboembolism After Elective Major Orthopedic Surgery of Hip or Knee

Sponsor: Bayer

Conditions Venous Thromboembolism

Interventions Rivaroxaban (Xarelto, BAY59-7939) Standard care treatment for VTE prophylaxis

Updated 8 times since 2017 Last updated: Jan 19, 2017 Started: Feb 28, 2009 Primary completion: Jun 30, 2011 Completion: Apr 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Venous Thromboembolism and is currently completed. Bayer leads this study, which shows 8 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed

▶ Show 3 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Feb 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

Feb 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer
Janssen Research & Development, LLC

Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Many Locations, Australia , Many Locations, Austria , Many Locations, Belgium , Many Locations, Bosnia and Herzegovina , Many Locations, Brazil , Many Locations, Canada , Many Locations, Chile , Many Locations, China , Many Locations, Colombia , Many Locations, Cyprus and 32 more locations